DDInter743 DDInter1628
Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Fluconazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Fluconazole {u} (Compound) downregulates {v} (Gene) DNTTIP2
DNTTIP2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Fluconazole {u} (Compound) downregulates {v} (Gene) ARFIP2
ARFIP2 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Fluconazole {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Fluconazole {u} (Compound) downregulates {v} (Gene) DNTTIP2
DNTTIP2 {u} (Gene) is regulated by {v} (Gene) IRAK1
IRAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Fluconazole {u} (Compound) downregulates {v} (Gene) PIGB
PIGB {u} (Gene) is upregulated by {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Fluconazole {u} (Compound) downregulates {v} (Gene) CASC3
CASC3 {u} (Gene) is associated with {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Fluconazole {u} (Compound) upregulates {v} (Gene) ABHD6
ABHD6 {u} (Gene) is downregulated by {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Fluconazole {u} (Compound) downregulates {v} (Gene) PIGB
PIGB {u} (Gene) is regulated by {v} (Gene) CEBPZ
CEBPZ {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Fluconazole {u} (Compound) downregulates {v} (Gene) CASC3
CASC3 {u} (Gene) regulates {v} (Gene) PHKG2
PHKG2 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Fluconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Fluconazole (Compound) downregulates DNTTIP2 (Gene) and DNTTIP2 (Gene) is upregulated by Ruxolitinib (Compound)
Fluconazole (Compound) downregulates ARFIP2 (Gene) and ARFIP2 (Gene) is downregulated by Ruxolitinib (Compound)
Fluconazole (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Fluconazole (Compound) downregulates DNTTIP2 (Gene) and DNTTIP2 (Gene) is regulated by IRAK1 (Gene) and IRAK1 (Gene) is bound by Ruxolitinib (Compound)
Fluconazole (Compound) downregulates PIGB (Gene) and PIGB (Gene) is upregulated by hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Fluconazole (Compound) downregulates CASC3 (Gene) and CASC3 (Gene) is associated with hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Fluconazole (Compound) upregulates ABHD6 (Gene) and ABHD6 (Gene) is downregulated by hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Fluconazole (Compound) downregulates PIGB (Gene) and PIGB (Gene) is regulated by CEBPZ (Gene) and CEBPZ (Gene) is upregulated by Ruxolitinib (Compound)
Fluconazole (Compound) downregulates CASC3 (Gene) and CASC3 (Gene) regulates PHKG2 (Gene) and PHKG2 (Gene) is bound by Ruxolitinib (Compound)